摘要
目的探讨康莱特注射液辅助NP化疗对非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效,并评估对患者免疫功能及生存质量的影响。方法选取NSCLC患者90例,随机分为对照组和观察组各45例。两组均采用NP化疗,观察组另给予康莱特注射液辅助治疗。两组患者均治疗2个NP化疗周期,评估患者生活质量、临床疗效、Ⅲ+Ⅳ度不良反应发生率和比较CEA、CA125和T淋巴细胞亚群水平。结果观察组患者客观缓解率(68.89%)高于对照组(55.56%),观察组患者Ⅲ+Ⅳ度不良反应总发生率(11.11%)低于对照组(24.44%),差异均有统计学意义(P<0.05);治疗后,观察组KPS评分高于对照组,观察组CEA、CA125、CD 8+均低于对照组,观察组CD 3+、CD 4+、CD 4+/CD 8+均高于对照组,差异均有统计学意义(P<0.05)。结论康莱特注射液辅助NP化疗能够提高NSCLC患者的临床疗效和生活质量,减轻不良反应和对免疫功能的损伤。
Objective To evaluate the clinical efficacy of Kanglaite injection assisted NP chemotherapy in treating non-small cell lung cancer(NSCLC) and the effect of the immune function and quality of life of the patients. Methods Firstly, 90 patients with NSCLC were chosen as the subjects and randomly divided into a control group(n=45) and an experimental group(n=45). The control group was subjected to NP chemotherapy while the experimental was subjected to Kanglaite injection in addition to NP chemotherapy. Both groups were subjected to two sessions of NP chemotherapy. Then, the quality of life, the clinical efficacy of treatment, the incidence of adverse reactions of Ⅲ+Ⅳ, the levels of CEA, CA125 and T lymphocyte subsets were assessed. Results The objective response rate of the experimental group(68.89%) was greater than that of the control group(55.56%). The total rate of incidence of Ⅲ+Ⅳ adverse reactions of the experimental group was 11.11%, which was lower than that of the control(24.44%). The differences were statistically significant(P<0.05). After treatment, the KPS score of the experimental group was greater than that of the control. The levels of CEA, CA125 and CD8+ of the experimental group were lower than those of the control group. The levels of CD3+, CD4+, CD4+/CD8+ of the experimental group were higher than those of the control group. The differences were statistically significant(P<0.05). Conclusions Kanglaite injection-assisted NP chemotherapy can improve the clinical efficacy and quality of life of NSCLC patients, alleviate adverse reactions and damage to immune function.
作者
王晓春
WANG Xiaochun(Department of Respiratory Medicine,the First People’s Hospital of Wuyi,Jinhua 321200,China)
出处
《健康研究》
CAS
2019年第5期559-562,共4页
Health Research
关键词
非小细胞肺癌
康莱特注射液
NP化疗
临床疗效
免疫功能
non-small cell lung cancer
Kanglaite injection
NP chemotherapy
clinical efficacy
immune function
